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To the Editor:   Proposed as potential mood-enhancing therapy [1], evidence linking statin use with 
depression remains conflicting [2].  Marked ethnic differences exist in rates of CVD, depression, and 
responses to some drugs [3,4], and yet ethnic minority groups (EMGs) have been under-represented in 
statin trials and no studies have examined ethnic differences in the statin-depression relationship. 
Cross-sectional data from a population-based tri-ethnic study [5] were available on 638 White Europeans, 
487 South Asians and 208 African-Caribbeans.  Depression (score of ≥4/10 on the ethnically-validated 
Geriatric Depression Scale [6]), and other psychosocial, behavioural, anthropometric and medication 
history data were collected.  Statin use was identified by prescription from participant/GP records (as were 
CVD and hypertension).  Diabetes was identified from medical record, diagnosis recall, or OGTT [5]. 
Statin use was modelled as a predictor for depression in logistic regression analyses, with ethnicity by statin 
use interaction terms included.  Models were also stratified by ethnicity.  In a 77% male sample (mean 
age=70), 56% of participants were receiving statins (48% White European, 68% South Asian, 52% African-
Caribbean).  Of those on statins, South Asian and African-Caribbean participants were significantly more 
likely to report depression compared with Europeans (OR 2.00 (95% CI 1.25-3.21) and 2.96 (1.67-5.24), 
respectively).  The similar relationship between statin use and depression in South Asians and African-
Caribbeans (Table 1) meant their data were pooled.  In ethnically-stratified model 1, statin use was not 
related to depression in Europeans, whereas among EMGs, depression was significantly higher in people on 
statins (full sample: ethnicity-statin interaction p=0.11).  After full adjustment, analyses showed a non-
significant trend towards a protective effect of statin use on depression in Europeans and a deleterious 
effect in EMGs (full sample: ethnicity-statin interaction,p=0.041). 
A few explanations could exist for this differential relationship between statin use and depression. 
‘Presentation bias’ (different presentation of depression by a particular ethnic group to healthcare 
professionals could increase the likelihood of detection/treatment of other conditions) was explored with 
depression somatisation, by correlating depressive symptoms with self-reported health.  No group 
demonstrated elevated depression somatisation, with the same strength and direction of relationship 
observed across all groups.  Depression was measured using a screening tool rather than clinical diagnosis; 
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often a study limitation, here it reduced ‘presentation bias’ likelihood, since depression may not have been 
discussed with GPs. 
Another possibility is that the statin-depression association was confounded by CVD due to the established 
bi-directional relationship between depression and CVD.  To examine whether, among EMGs, depression is 
a stronger predictor of CVD or vice versa, we adjusted for CVD in the main models (4-5) and stratified the 
fully-adjusted model by CVD status in sensitivity analyses.  The same results were observed across groups 
irrespective of CVD prevalence (results not shown), indicating that the statin-depression link did not result 
from statin use acting as a proxy for CVD. 
Therefore, our results may reflect a true ethnic difference in the impact of statins on depression.  Ethnic 
differences in response to statins could elicit direct and indirect effects on depression, i.e. across 
ethnicities, there could be a differential influence of statins on lipid sub-fractions or of statins’ protective 
effects on cerebrovascular processes, both of which could impact mood.  Alternatively, EMGs could be 
more vulnerable to statin-induced side-effects, influencing depression. 
EMGs receiving statins in this sample were over twice as likely to report depression as Europeans.  To our 
knowledge, this is the first study to examine ethnic differentials in the statin-depression relationship.  We 
acknowledge our dataset’s limitations, in particular its cross-sectional nature precluding causal 
interpretations and limited study power; however our aim is to highlight these findings and urge others to 
interrogate existing clinical trial/healthcare databases, as well as including sufficient EMG numbers in 
future studies.  Given the pervasiveness of statins and predisposition towards CVD and depression among 
certain groups [3,4], this finding has potentially serious implications for the mental health of thousands of 
EMGs being treated with statins. 
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Table 1: Risk of major depression according to statin use across ethnic groups  
 White European 
(n = 638) 
South Asian and  
African Caribbean∏                      
(n = 695) 
 
Not on statins - % depressed  9.6 11.9  
On statins - % depressed 9.8 19.5*  
 Risk of depression according to statin use 
 
Ethnic-
statin 
interaction  
 OR (95% CI) p value 
    
Model 1: age and sex  1.03 (0.60-1.76) 1.91 (1.22-3.01) 0.11 
Model 2: model 1 + manual labour 
and stressful life events 
0.96 (0.56-1.65) 1.89 (1.20-2.99) 0.087 
Model 3: model 1 + smoking, alcohol 
intake and physical activity  
0.84 (0.47-1.49) 1.81 (1.14-2.87) 0.085 
Model 4: model 1 + BMI, diabetes, 
hypertension and CVD 
0.58 (0.29-1.15) 1.66 (0.98-2.83) 0.036 
Model 5: Full adjustment  0.54 (0.26-1.13) 1.67 (0.97-2.88) 0.041 
In sample with total cholesterol > 3mmol/L∑:   
Full adjustment  0.52 (0.24-1.13) 1.60 (0.91-2.79) 0.049 
*significant ethnic group difference of p<0.05. BMI: body mass index. CVD: cardiovascular disease.   ∏ South Asians 
only:  % depressed - Not on statins=10.2%, on statins=17.9%*. For African Caribbeans only: % depressed - Not on 
statins=14.6%, on statins=24.8%*.   South Asians only:  OR 1.94 (1.07-3.52), p=0.13 for ethnic-statin interaction.  
African Caribbeans only: OR 2.19 (1.05-4.57), p=0.16 for ethnic-statin interaction. ∑ To assess the potential 
confounding role of very low cholesterol, the sample was restricted to those participants with total cholesterol of 
>3mmol/L. 
 
